The chairman of GlaxoSmithKline Nigeria Plc, Olusegun Osunkeye,
yesterday attributed the rise in the shares of the company in the nation’s capital market as well as the decision to divest its investment from Lucozade and Ribena globally as the major reasons GlaxoSmithKline UK withdrew its earlier plans to stake over N3billion on acquisition of additional 25 per cent in its Nigeria subsidiary, GlaxoSmithKline Consumer Nigeria Plc.
